ANL
NASDAQAdlai Nortye Ltd.
Price$10.37-0.21 (-1.99%)
02:00 PM07:45 PM
News · 26 weeks32-12%
2025-12-142026-06-07
Mix2090d
- Insider10(50%)
- Other5(25%)
- SEC Filings3(15%)
- Analyst2(10%)
Latest news
25 items- INSIDERDirector Ji Ping acquired 136,667 units of American Depository shares (SEC Form 4)4 - Adlai Nortye Ltd. (0001944552) (Issuer)
- INSIDERNew insider Ye Xiaofeng claimed ownership of 159,455 units of American Depositary Shares (SEC Form 3)3 - Adlai Nortye Ltd. (0001944552) (Issuer)
- INSIDERSEC Form 3 filed by new insider Tse Alan Ming Lun3 - Adlai Nortye Ltd. (0001944552) (Issuer)
- ANALYSTOppenheimer initiated coverage on Adlai Nortye Ltd. with a new price targetOppenheimer initiated coverage of Adlai Nortye Ltd. with a rating of Outperform and set a new price target of $32.00
- INSIDERCEO Lu Yang sold $132 worth of American Depositary Shares (10 units at $13.18), decreasing direct ownership by 0.01% to 99,990 units (SEC Form 4)4 - Adlai Nortye Ltd. (0001944552) (Issuer)
- INSIDERNew insider Lu Yang claimed ownership of 100,000 units of American Depositary Shares and claimed ownership of 16,990,000 units of Class B ordinary shares (SEC Form 3)3 - Adlai Nortye Ltd. (0001944552) (Issuer)
- INSIDERNew insider Tse Archie claimed ownership of 50,000 units of American Depository Share (SEC Form 3)3 - Adlai Nortye Ltd. (0001944552) (Issuer)
- SECSEC Form SCHEDULE 13G filed by Adlai Nortye Ltd.SCHEDULE 13G - Adlai Nortye Ltd. (0001944552) (Subject)
- INSIDERAmendment: SEC Form 3 filed by new insider Tang Kaiyang3/A - Adlai Nortye Ltd. (0001944552) (Issuer)
- INSIDERAmendment: SEC Form 3 filed by new insider Ji Ping3/A - Adlai Nortye Ltd. (0001944552) (Issuer)
- INSIDERSEC Form 3 filed by new insider Tang Kaiyang3 - Adlai Nortye Ltd. (0001944552) (Issuer)
- INSIDERSEC Form 3 filed by new insider Ji Ping3 - Adlai Nortye Ltd. (0001944552) (Issuer)
- SECSEC Form EFFECT filed by Adlai Nortye Ltd.EFFECT - Adlai Nortye Ltd. (0001944552) (Filer)
- SECAmendment: SEC Form F-3/A filed by Adlai Nortye Ltd.F-3/A - Adlai Nortye Ltd. (0001944552) (Filer)
- SECAmendment: SEC Form F-3/A filed by Adlai Nortye Ltd.F-3/A - Adlai Nortye Ltd. (0001944552) (Filer)
- SECSEC Form 6-K filed by Adlai Nortye Ltd.6-K - Adlai Nortye Ltd. (0001944552) (Filer)
- PRAdlai Nortye Announces $150.0 Million Private Placement Equity FinancingSINGAPORE and NORTH BRUNSWICK, N.J., April 16, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ:ANL) (the "Company" or "Adlai Nortye"), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that it has entered into a securities purchase agreement for a private investment in public equity financing that is expected to result in gross proceeds of approximately $150.0 million, before deducting placement agent fees and other private placement expenses. The oversubscribed transaction includes participation from both new and existing institutional investors. New investors include Soleus Capital, Perceptive Advisors, ADAR1 Capital Man
- SECSEC Form 20-F filed by Adlai Nortye Ltd.20-F - Adlai Nortye Ltd. (0001944552) (Filer)
- SECSEC Form 6-K filed by Adlai Nortye Ltd.6-K - Adlai Nortye Ltd. (0001944552) (Filer)
- ANALYSTLeerink Partners initiated coverage on Adlai Nortye Ltd. with a new price targetLeerink Partners initiated coverage of Adlai Nortye Ltd. with a rating of Outperform and set a new price target of $23.00
- SECSEC Form F-3 filed by Adlai Nortye Ltd.F-3 - Adlai Nortye Ltd. (0001944552) (Filer)
- ANALYSTAdlai Nortye Ltd. upgraded by H.C. Wainwright with a new price targetH.C. Wainwright upgraded Adlai Nortye Ltd. from Neutral to Buy and set a new price target of $16.00
- SECSEC Form 6-K filed by Adlai Nortye Ltd.6-K - Adlai Nortye Ltd. (0001944552) (Filer)
- PRAdlai Nortye Announces First Patient Enrolled in Global Phase 1 Trial of Pan-RAS (ON) Inhibitor AN9025 for Solid Tumors Harboring RAS MutationsSINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ:ANL) (the "Company" or "Adlai Nortye"), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that the first patient has been dosed in the United States in early February in its ongoing Phase 1 clinical trial of AN9025, a pan-RAS (ON) inhibitor. The Phase 1 study is a first-in-human, multicenter, open-label trial designed to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of AN9025 in patients with advanced or metastatic solid tumors harboring RAS mutations. This trial is being conducted
- SECSEC Form SCHEDULE 13G filed by Adlai Nortye Ltd.SCHEDULE 13G - Adlai Nortye Ltd. (0001944552) (Subject)
ANL FAQ
6 questionsWhere does ANL stock trade?
Adlai Nortye Ltd. (ANL) is listed on NASDAQ.What sector and industry is ANL in?
Adlai Nortye Ltd. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Adlai Nortye Ltd. go public?
Adlai Nortye Ltd. (ANL) completed its IPO in 2023.What are analysts saying about ANL?
Adlai Nortye Ltd. has had 6 recent analyst actions on file. The most recent action was from Oppenheimer: Outperform with a $3200.00 price target on 2026-05-28. Recent price targets range from $900.00 to $3200.00.What companies are similar to ANL?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare ANL side-by-side with any of them on Quantisnow.How can I track ANL on Quantisnow?
Quantisnow aggregates Adlai Nortye Ltd.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ANL to receive live email and push alerts on every new disclosure.